Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

Phase 1, open-label, single-arm trial of gemcitabine, Cisplatin micelle injection (HA132) and durvalumab in biliary tract cancer (BTC) and cholangiocarcinoma (CCA), sponsored by University of Maryland, Baltimore. Primary endpoints: Number of adverse events assessment by CTCAE v5.0 that are grade 3 or higher and related to HT or SFRT and Number of participants to receive a minimum of 30 minutes of heating at target temperature (39-43°C) for at least 2 of the planned 3 deep HT treatments. Started Oct 2024; status: recruiting.